HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma
- 538 Downloads
The distinction between primary gastric adenocarcinoma and gastric metastatic breast carcinoma can be difficult. Expression of hepatocyte nuclear factor 4A (HNF4A) has been described as being specific to distinguish between neoplastic gastric and breast epithelial cells. The aim of this study was to validate the use of HNF4A with immunohistochemistry in discriminating gastric from breast carcinomas. Immunohistochemical expressions of HNF4A, estrogen receptor (ER), progesterone receptor (PR), and BRST-2 were determined in primary sporadic gastric adenocarcinomas (n = 107) and breast carcinomas (n = 105). The same markers and clinicopathological features were studied in 1 patient with breast metastasis of gastric cancer, 6 patients with gastric metastases of breast cancer, and 13 patients with both primary gastric and breast carcinomas. HNF4A expression was seen in 106 of 107 primary gastric adenocarcinomas and was absent in all 105 primary breast carcinomas (sensitivity 99 %, specificity 100 %). ER, PR, and BRST-2 were 100 % specific for breast carcinomas with sensitivities of 77, 58, and 38 %, respectively. The metastasis of gastric carcinoma to the breast showed strong expression of HNF4A. None of the metastases of breast carcinomas to the stomach showed expression of HNF4A. Tissues of patients with two primary carcinomas showed strong expression of HNF4A in all gastric carcinomas and no expression in breast carcinomas. Our results indicate that HNF4A is a very good marker to discriminate between primary and metastatic gastric and breast carcinomas.
KeywordsImmunohistochemistry HNF4A Gastric carcinoma Breast carcinoma
The authors would like to thank Monique Link (technical assistance).
Conflict of interest
The authors have no competing interests.
- 1.Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444, 2010/07/02 edn. doi: 10.1136/jmg.2009.074237 PubMedCentralPubMedCrossRefGoogle Scholar
- 3.Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Nogues C, Fourme E, Colas C, Coulet F, Warcoin M, Grandjouan S, Sezeur A, Laurent-Puig P, Moliere D, Tlemsani C, Di Maria M, Byrde V, Delaloge S, Blayau M, Caron O (2013) CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet 50:486–489, 2013/05/28 edn. doi: 10.1136/jmedgenet-2012-101472 PubMedCrossRefGoogle Scholar
- 4.Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, Gorski B, Cybulski C, Debniak T, Kowalska E, Starzynska T, Lawniczak M, Narod S, Lubinski J (2003) A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 11:955–958, 2003/12/03 edn. doi: 10.1038/sj.ejhg.5201064 PubMedCrossRefGoogle Scholar
- 11.Almubarak MM, Lae M, Cacheux W, de Cremoux P, Pierga JY, Reyal F, Bennett SP, Falcou MC, Salmon RJ, Baranger B, Mariani P (2011) Gastric metastasis of breast cancer: a single centre retrospective study. Dig Liver Dis 43:823–827, 2011/05/28 edn. doi: 10.1016/j.dld.2011.04.009 PubMedCrossRefGoogle Scholar
- 12.BG Taal, FC den Hartog Jager, R Steinmetz and H Peterse (1992) The spectrum of gastrointestinal metastases of breast carcinoma: I. Stomach. Gastrointest Endosc, vol 38, 1992/03/01 edn.,Google Scholar
- 16.Koyama T, Sekine S, Taniguchi H, Tsuda H, Ikegami M, Hano H, Kushima R (2011) Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas. Hum Pathol 42:1777–1784, 2011/07/08 edn. doi: 10.1016/j.humpath.2011.04.002 PubMedCrossRefGoogle Scholar
- 17.Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M, Ishikura H (2006) The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology 38:548–554, 2007/03/31 ednPubMedCrossRefGoogle Scholar
- 18.Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, Daigo K, Ohashi R, Sugai M, Ikegame C, Umezu H, Hirayama Y, Midorikawa Y, Hippo Y, Watanabe A, Uchiyama Y, Hasegawa G, Reid P, Aburatani H, Hamakubo T, Sakai J, Naito M, Kodama T (2006) Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol 208:662–672, 2006/01/10 edn. doi: 10.1002/path.1928 PubMedCrossRefGoogle Scholar
- 20.Takano K, Hasegawa G, Jiang S, Kurosaki I, Hatakeyama K, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M (2009) Immunohistochemical staining for P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha may complement mucin phenotype of differentiated-type early gastric carcinoma. Pathol Int 59:462–470, 2009/07/01 edn. doi: 10.1111/j.1440-1827.2009.02394.x PubMedCrossRefGoogle Scholar
- 27.Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11:3766–3772, 2005/05/18 edn. doi: 10.1158/1078-0432.ccr-04-2236 PubMedCrossRefGoogle Scholar